期刊
TISSUE ENGINEERING AND REGENERATIVE MEDICINE
卷 17, 期 5, 页码 683-693出版社
KOREAN TISSUE ENGINEERING REGENERATIVE MEDICINE SOC
DOI: 10.1007/s13770-020-00276-2
关键词
BM-MSCs; Erythropoietin; Migration; Anti-fibrosis efficacy; Liver fibrosis
资金
- Foundation of Guizhou Provincial Department of Science and Technology [[2017] 2873, [2017] 5718]
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2018PT31048]
- Science and Technology project of Guiyang City [ZKHT [2017]-5-10]
- Guizhou Province Science and Technology supporting Plan [[2018] 2757]
Background: Mesenchymal stem cell (MSC)-based cell transplantation is an effective means of treating chronic liver injury, fibrosis and end-stage liver disease. However, extensive studies have found that only a small number of transplanted cells migrate to the site of injury or lesion, and repair efficacy is very limited. Methods: Bone marrow-derived MSCs (BM-MSCs) were generated that overexpressed the erythropoietin (EPO) gene using a lentivirus. Cell Counting Kit-8 was used to detect the viability of BM-MSCs after overexpressing EPO. Cell migration and apoptosis were verified using Boyden chamber and flow cytometry, respectively. Finally, the anti-fibrosis efficacy of EPO-MSCs was evaluatedin vivousing immunohistochemical analysis. Results: EPO overexpression promoted cell viability and migration of BM-MSCs without inducing apoptosis, and EPO-MSC treatment significantly alleviated liver fibrosis in a carbon tetrachloride (CCl4) induced mouse liver fibrosis model. Conclusion: EPO-MSCs enhance anti-fibrotic efficacy, with higher cell viability and stronger migration ability compared with treatment with BM-MSCs only. These findings support improving the efficiency of MSCs transplantation as a potential therapeutic strategy for liver fibrosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据